Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotine patch + nicotine lozenge is a combination of two forms of nicotine replacement therapy (NRT) used to aid in smoking cessation. Both deliver controlled amounts of pharmaceutical-grade nicotine to reduce withdrawal symptoms and cravings associated with quitting tobacco. The transdermal patch provides a steady release of nicotine through the skin over 16–24 hours, while the oral lozenge delivers rapid relief by dissolving in the mouth and allowing absorption through the oral mucosa. This dual approach targets both baseline withdrawal and acute cravings. The primary indication is for smoking cessation in adults[2][3][4][5]. Mechanistically, both products act as agonists at nicotinic acetylcholine receptors to substitute for tobacco-derived nicotine and mitigate dependence-related symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nicotine patch + nicotine lozenge.